DXCM - DexCom, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
120.66
-2.36 (-1.92%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close123.02
Open121.95
Bid116.00 x 800
Ask125.00 x 2200
Day's Range119.40 - 123.32
52 Week Range51.04 - 152.14
Volume896,170
Avg. Volume1,585,626
Market Cap10.72B
Beta (3Y Monthly)0.95
PE Ratio (TTM)249.30
EPS (TTM)0.48
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est150.56
Trade prices are not sourced from all markets
  • 3 Top Medical Device Stocks to Buy Now
    Motley Fool3 days ago

    3 Top Medical Device Stocks to Buy Now

    Align Technology, NovoCure, and DexCom look poised for explosive growth.

  • Zacks3 days ago

    5 Stocks That Popped More Than 100% in 2018 Defying All Odds

    Five solid picks that defied the problems confronting the U.S. economy.

  • Hedge Funds Are Betting On DexCom, Inc. (DXCM)
    Insider Monkey5 days ago

    Hedge Funds Are Betting On DexCom, Inc. (DXCM)

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]

  • Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
    Zacks5 days ago

    Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

    Is (DXCM) Outperforming Other Medical Stocks This Year?

  • Zacks5 days ago

    What Falling Estimates & Price Mean for Alphatec Holdings (ATEC)

    Alphatec Holdings (ATEC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • InvestorPlace10 days ago

    2 Internet of Things Stocks to Buy for the Connected Future

    The “Internet of Things” is already a fairly well-known term, but by next year, I expect it will be a phrase used in every household. The reach of the IoT is massive, which should might have investors asking themselves what are some good Internet of Things stocks to buy? IoT includes the commonly thought of devices like smartphones and televisions, as well as new possibilities such as thermostats, automobiles and even street lights.

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: DexCom and BioTelemetry

    NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...

  • GlobeNewswire16 days ago

    Detailed Research: Economic Perspectives on Broadridge Financial Solutions, MercadoLibre, Rogers, Ensco plc, Liberty Oilfield Services, and DexCom — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • 5 Stocks to Gain as Fed Chair "Blinks" on Rates
    Zacks16 days ago

    5 Stocks to Gain as Fed Chair "Blinks" on Rates

    Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks.

  • A Closer Look at Dexcom Stock’s 117% Year-to-Date Growth
    Market Realist17 days ago

    A Closer Look at Dexcom Stock’s 117% Year-to-Date Growth

    Dexcom hit its 52-week high of $152.14 on November 8. In October, Dexcom announced that the US Centers for Medicare & Medicaid Services would cover the new Dexcom G6 Continuous Glucose Monitoring System for Medicare beneficiaries. Dexcom expects to initiate delivery to Medicare beneficiaries in the first half of 2019.

  • Tandem Diabetes Care Stock Has Skyrocketed in 2018
    Market Realist17 days ago

    Tandem Diabetes Care Stock Has Skyrocketed in 2018

    On November 21, Tandem Diabetes Care (TNDM) stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

  • Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel
    Zacks17 days ago

    Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel

    Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel

  • Business Wire17 days ago

    DexCom Prices Offering of $750.0 Million of 0.75% Convertible Senior Notes

    DexCom, Inc. (DXCM) (“DexCom”) announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $100.0 million aggregate principal amount of notes. The notes will be senior, unsecured obligations of DexCom, and will bear interest at a rate of 0.75% per year, payable semi-annually in arrears.

  • 4 Profitable Stocks Boasting Amazingly High Net Income Ratio
    Zacks18 days ago

    4 Profitable Stocks Boasting Amazingly High Net Income Ratio

    Profitability analysis is considered one of the best possible ways to assess the prospects of a company.

  • Business Wire19 days ago

    DexCom Announces Proposed Offering of $750 Million of Convertible Senior Notes

    DexCom, Inc. (DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $750 million aggregate principal amount of Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $100 million aggregate principal amount of notes. The notes will be senior, unsecured obligations of DexCom, and interest will be payable semi-annually in arrears.

  • Here's Why Investors Should Bet on DexCom (DXCM) Right Now
    Zacks19 days ago

    Here's Why Investors Should Bet on DexCom (DXCM) Right Now

    DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.

  • DexCom Amends Deal With Verily to Launch Advanced CGM by 2020
    Zacks23 days ago

    DexCom Amends Deal With Verily to Launch Advanced CGM by 2020

    DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.

  • How Should Investors Feel About DexCom Inc’s (NASDAQ:DXCM) CEO Pay?
    Simply Wall St.24 days ago

    How Should Investors Feel About DexCom Inc’s (NASDAQ:DXCM) CEO Pay?

    Kevin Sayer has been the CEO of DexCom Inc (NASDAQ:DXCM) since 2015. First, this article will compare CEO compensation with compensation at other large companies. Then we’ll look at a Read More...

  • Business Wire24 days ago

    DexCom Announces Upcoming Conference Presentation

    DexCom, Inc. today announced that management will present an update on Dexcom at the following upcoming investor conference:

  • Benzinga24 days ago

    The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...

  • Business Wire25 days ago

    Dexcom and Verily Amend Collaboration and License Agreement

    DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), and Verily, an Alphabet company, announced an amendment to the Collaboration and License Agreement surrounding the ongoing development efforts between the companies. The revised terms are intended to reinforce the companies’ mutual product development goals, while expanding options for future collaborations. The agreement also accelerates Dexcom’s efforts to advance into the Type 2 diabetes space and improves its future profitability.

  • Alphabet Halts Glucose Lens Work to Focus on Other Projects
    Zacks26 days ago

    Alphabet Halts Glucose Lens Work to Focus on Other Projects

    Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.

  • Investopedia29 days ago

    DexCom Stock Could Continue to Climb

    DexCom, Inc. ( DXCM), a medical device company, is having one heck of a year. The stock is up over 100% since Jan. 1, but it has even more room to climb, although many investors will look at a high-flying stock like DexCom and assume that it's overbought and destined to collapse from here. Right now, the stock is forming one of my favorite stock patterns: an ascending triangle, which signals that more gains are still to come.

  • Why Wall Street Is Still Bullish on Tandem Stock
    Market Realistlast month

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.